Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Living cheaply while in debt is possible with the right strategies. Discover how to manage your finances effectively during tough times.
28,482 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A fund’s big move out of a top-performing pharma stock can puzzle investors. Here’s a clear, practical look at what k...
A real-world move shows an investment advisor trims small-cap exposure by millions, signaling risk management and str...
Dogecoin slips again, but a niche on-chain model points to a long-term accumulation floor. As traders debate a possib...
At a White House ceremony on President Trump’s 80th birthday, trump-backed World Liberty Financial announced a USD1 s...
Oil prices slide to the low $70s as Middle East risk cools, fueling debates on whether the Federal Reserve has paused...
The Fed kept its policy rate unchanged, setting the stage for a slow drift in HYSA yields. Savers await any signal fr...
July 16 could be a pivotal date for Nvidia and the broader AI chip ecosystem. This guide explains why Nvidia investor...
This analysis breaks down what investors should watch in first horizon (fhn) 2026 earnings, with clear guidance on me...
A major government contract marks a turning point for Palantir. This analysis explains how the DHS deal could reshape...
A federal judge dismissed the Binance terrorism lawsuit, citing lack of direct links to specific attacks. The ruling ...
Super Micro Computer delivered a blowout Q2 as AI infrastructure demand drives orders for its Data Center Building Bl...